The global anaemia treatment market is estimated to be valued at USD 12.45 billion in 2025 and is projected to reach USD 22.08 billion by 2035, registering a compound annual growth rate (CAGR) of 5.9% over the forecast period. The anemia treatment market is experiencing steady growth, driven by increasing global prevalence of iron deficiency anemia, anemia of chronic disease, and renal anemia. Rising diagnosis rates, particularly among aging populations and individuals with chronic kidney disease, are expanding treatment-eligible patient pools.
Innovative erythropoiesis-stimulating agents (ESAs), intravenous iron formulations and emerging hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are transforming clinical management protocols. Alternatively, expanded screening programs for anemia in women’s health, paediatric care, and oncology supportive care are increasing early intervention rates. Industry partnerships with nephrology and oncology clinics are improving drug accessibility and thus boosting market growth.
Key players shaping the anemia treatment market include Astellas, Akebia Therapeutics, Vifor Pharma, GSK, and CSL Vifor, who are driving innovation through HIF-PHI development, novel IV iron products, and next-gen ESAs. In 2024, Vafseo® approved by the USA FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients. "We congratulate our partner Akebia on the FDA approval, which represents an important moment in our shared efforts toward improving the lives of dialysis patients with anemia due to CKD in the USA," said Hervé Gisserot, General Manager of CSL Vifor.
"As we continue to deliver on our promise for patients and public health, we are eager to closely collaborate with our partners to make this new oral treatment option available to patients." The expanding availability of oral therapies is expected to reduce dependence on injectable ESAs, optimize patient compliance, and shift treatment into outpatient and home-care settings, thereby expanding the commercial footprint for biopharma companies targeting multiple anemia subtypes globally.
North America dominates the anemia treatment market, largely due to the region’s high prevalence of anemia among CKD, oncology, and geriatric populations. The 2024 FDA approval of oral HIF-PHIs has opened new outpatient treatment pathways, reducing the reliance on dialysis-center-based ESA administration. Additionally, strategic partnerships between biopharma companies and large nephrology care networks are driving rapid adoption of novel anemia treatments across integrated care models.
Europe is witnessing accelerated growth in anemia treatment driven by national healthcare policies targeting chronic disease management and maternal health programs. The EMA's conditional approvals for newer oral HIF-PHIs and advanced IV iron therapies have expanded clinician options beyond traditional ESA therapies.
Germany and France are the most lucrative market high adoption of outpatient anemia management protocols within nephrology and oncology clinics, supported by strong reimbursement frameworks under national health systems. The shift towards home-based anemia management for stable CKD and elderly patients is creating new commercial channels for biopharma manufacturers across both the regions
A comparative analysis of fluctuations in compound annual growth rate (CAGR) for the anemia treatment market between 2024 and 2025 on a six-month basis is shown below. By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market’s growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December.
The table below compares the compound annual growth rate (CAGR) for the global anemia treatment industry analysis from 2024 to 2025 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 7.6%, followed by a slightly lower growth rate of 7.3% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.6% (2024 to 2034) |
| H2 | 7.3% (2024 to 2034) |
| H1 | 6.9% (2025 to 2035) |
| H2 | 6.4% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 6.9% in the first half and projected to lower at 6.4% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
In 2025, normocytic anemia (normal MCV) is projected to hold 71.3% of the revenue share in the anemia treatment market. This dominance is largely due to the high prevalence of normocytic anemia, which is commonly associated with chronic diseases, including chronic kidney disease, cancer, and inflammatory disorders. Unlike microcytic anemia, which is often caused by iron deficiency, normocytic anemia presents with normal red blood cell size but a reduced number of red blood cells.
The treatment for normocytic anemia typically focuses on addressing the underlying chronic condition, often requiring the use of erythropoiesis-stimulating agents (ESAs) and other targeted therapies. The growing number of patients diagnosed with chronic conditions that lead to normocytic anemia, especially as the global aging population increases, has driven demand for these treatment options. Furthermore, advancements in injectable therapies and better understanding of disease pathophysiology have enhanced the management of normocytic anemia, further solidifying the segment’s dominance in the market.
In 2025, the injectable route is expected to capture 58.6% of the revenue share in the anemia treatment market. This leadership is attributed to the high efficacy and fast-acting nature of injectable treatments, particularly in patients who require rapid relief from anemia symptoms. Injectable therapies, such as erythropoiesis-stimulating agents (ESAs) and iron infusions, provide a direct and efficient delivery method, ensuring that the medication is absorbed quickly and effectively into the bloodstream.
The growing demand for injectable treatments has been fueled by the need for more personalized and intensive management of anemia, especially in patients with chronic kidney disease, cancer, or other severe conditions. Moreover, injectable therapies offer better control over dosages and treatment regimens compared to oral formulations, making them the preferred choice for patients with severe or treatment-resistant anemia. The increasing adoption of injectable therapies in both inpatient and outpatient settings has further contributed to the growth of this segment in the anemia treatment market.
Improved Nutritional Education Contribute to the growth of Anemia Treatment
Improved nutritional education has been one of the major factors in the growth of anemia treatment adoption. As people have become more aware of the importance of a balanced diet, they have become more conscious of the nutrients required to prevent and treat anemia. Public health campaigns and educational programs have significantly promoted these nutrients, especially among vulnerable groups poor dietary habits.
Such educational help has reduced the root cause of anemia, such as iron deficiency common in many places, and educated them about iron-rich foods and enhancing iron absorption using vitamin C so that they would be able to make informed diet choices. In addition, nutritionists and health care professionals have emphasized specific anemia-related conditions, such as vitamin B12 deficiency in older adults and pregnant women, which has called for early diagnosis and treatment.
As knowledge related to the relationships between nutrition and anemia expands, more patients seek guidance and treatment for anemia, thus fostering overall growth in the adoption of anemia treatments. Improved education on nutrition enhances people's capacity to take positive action in anemia prevention and management, ultimately driving greater demand for effective treatments.
Improved Diagnosis of Anemia Anticipate the Growth in Adoption of Anemia Treatment
Improved diagnosis of anemia has significant growth in adopting the treatment for anemia owing to the fact that early diagnosis and more precise determination of the disease can be performed. Advancement in the field of diagnostics technologies such as automated blood tests, hemoglobin electrophoresis, allows detection of anemia in its very early stages by the medical care provider. It also aid in diagnosis of patients that are pregnant and people suffering from chronic diseases.
Early diagnostics help in determination of specific form of anemia, which might be iron deficiency anemia, vitamin B12 deficiency anemia, or anemia caused due to chronic diseases. This makes for a more effective form of treatment by targeting the need of each patient.
The increased accuracy and availability of diagnostic tests have also helped reduce the stigma surrounding anemia, as people are more likely to seek care once they understand the condition and its manageable nature. Consequently, the adoption of treatments, such as iron supplements, vitamin B12 injections, or blood transfusions, has grown, improving overall public health outcomes and reducing the burden of anemia globally.
Emphasis on Development of Targeted Therapies Poses Significant Business Opportunities in Anemia Treatment Market
This market, especially in terms of the emphasis placed on developing targeted therapies for the treatment of anemia, represents a considerable business opportunity, targeting specific causes that underlie this condition, with better patient outcomes and treatment compliance. Targeted therapies are designed to offer patients more individualized care through improved iron supplements that have fewer side effects or innovative drugs for the management of chronic diseases-related anemia.
By tailoring treatments to specific types of anemia-whether due to iron, vitamin B12, or folate deficiencies, or as a result of chronic conditions like kidney disease or cancer-pharmaceutical companies can create more effective solutions that address individual patient needs.
For instance, the newer preparations of oral iron supplementation that have less gastrointestinal side effects or intravenous iron therapies where patients can receive their treatment quicker and more effectively set apart from conventional treatments. Finally, improvement in ESAs for patients suffering from anemia resulting from chronic kidney disease or due to the chemotherapy process of cancer treatment has potential for developing specific therapy in these populations with high risks of anemia.
This growing trend in personalized healthcare provides significant growth potential for businesses that develop innovative, targeted anemia therapies to meet the evolving needs of patients.
Side Effects Associated with Existing Treatment Hinders the Growth of Anemia Treatment
Oral iron supplements are considered the most popular treatment for iron-deficiency anemia. In many cases, these supplements tend to cause a range of side effects such as constipation, nausea, and discomfort in the abdomen, which drives patients to withdraw from their prescription or reduce it. Due to these side effects, poor adherence to treatment brings about suboptimal therapeutic outcomes and prolonged anemia, which can further impact patient health.
IV iron infusions or ESAs might be prescribed in more severe cases, mainly because intravenous ferric carboxymaltose was found to be effective in women with low ferritin levels and anemia due to chronic diseases. Although these treatments are better, they have their risks, side effects, such as allergic reaction, fever, and hypertension. Both healthcare providers and patients fear the risks, thus are often reluctant to accept the therapy.
This, in turn, limits the uptake of treatment, reduces patient adherence, and often leads to alternative treatments or dose adjustments. These factors contribute to slower market growth as patients may seek other, potentially less effective solutions or avoid treatment altogether.
Tier 1 companies are the major companies as they hold a 56.1% share worldwide. Tier 1 companies benefit from large-scale production facilities, significant investments in research and development, and extensive distribution networks, positioning them as leaders in innovation and market leadership.
Their ability to scale production and meet high consumer demand has solidified their position in the market. Prominent companies within tier 1 include Pfizer Inc., Janssen Pharmaceuticals, Inc., Amgen Inc.
Tier 2 companies are relatively smaller as compared with tier 1 players. The tier 2 companies hold a share of 28.1% worldwide. Tier 2 companies, while smaller in scale compared to Tier 1, continue to play a crucial role during the anemia treatment industry analysis.
These companies focus on specific or emerging market niches, providing specialized products or solutions targeted toward regional markets or specialized consumer needs. Their strength lies in their agility and ability to develop innovative solutions for underserved or niche segments of the market. Key Companies under this category include Hoffmann-La Roche Ltd., AMAG Pharmaceuticals and Rockwell Medical.
The section below covers the industry analysis for the anemia treatment sales for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 1.5% through 2035. In South Asia & Pacific, India is projected to witness the highest CAGR in the market of 5.4% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 1.5% |
| Germany | 1.6% |
| France | 2.4% |
| UK | 1.7% |
| Japan | 5.4% |
| China | 4.8% |
The United States dominates the global market with high share in 2024. The United States is expected to exhibit a CAGR of 1.5% throughout the forecast period (2025 to 2035).
Improved treatments and medications for anemia are set to significantly spur the growth of anemia treatment in the United States. Better pharmaceuticals, such as erythropoiesis-stimulating agents and iron therapies, have improved the efficacy and efficiency of managing anemia, improving patient outcomes.
These innovations have been more targeted and personalized to address different types of anemia, including iron-deficiency anemia, pernicious anemia, and anemia of chronic disease. The development of oral iron supplements with fewer side effects and increased use of intravenous iron therapies allow for better compliance by the patients and quicker recovery.
The increasing awareness of anemia's effect on quality of life, particularly among the aging population and chronic patients, is expected to spur demand with the availability of improved treatments. Better awareness and earlier diagnosis will push more people towards effective treatments, which will lead to growth in the market and increase access to care across the country.
In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 1.6%.
Availability of treatments such as erythropoiesis-stimulating agents (ESAs), iron supplements, and gene therapies provide effective and personalized solutions for anemia patients. These innovations lead to improved patient outcomes, which leads to increase in demand for anemia treatments.
Advanced treatments have been accepted and adopted easily because of the powerful health system of Germany along with high levels of awareness concerning the treatment. An aging population also increases vulnerability towards anemia; therefore, more demand arises for better solutions to treat such medical conditions.
It makes the quality of life for patients better and decreases the overall burden on healthcare, making these treatments more attractive to both providers and patients. As a result, the increasing availability of advanced treatments fosters market expansion and positions Germany as a key player in the anemia treatment sector.
Japan occupies a leading value share in East Asia market in 2024 and is expected to grow with a CAGR of 5.4% during the forecasted period.
Japan is increasing the importance of preventive health care. Anemia treatment, in general, is boosted because Japan's healthcare system focuses on periodic check-ups and screening for a range of diseases, including anemia. Thus, this proactive healthcare approach helps to detect anemia at an early stage, henceforth allowing prompt intervention and treatment.
In turn, the number of individuals diagnosed with the condition and started on treatment increases before it reaches a severe state. Preventive healthcare also increases public awareness of the dangers and symptoms of anemia, which encourages people to seek medical advice sooner. In addition, this preventive approach is in line with Japan's overall objective of enhancing health outcomes and reducing the burden on healthcare systems by addressing problems early.
With anemia identified and controlled by prevention measures, advanced treatments have gained significant traction and continue to contribute to market growth as well as the overall patient outcomes within the country.
The anemia treatment market is highly competitive, with both established leaders and new players constantly vying for market share. Leading companies focus on offering cutting-edge solutions by collaborating with the established players that combine advanced technology for production anticipate the growth of the market. Many of these competitors are also emphasizing on receiving regulatory approval for their products for strengthening their market share.
Recent Industry Developments in Anemia Treatment Market
In terms of treatment, the industry is divided into medications and dietary supplements
In terms of disease type, the industry is divided into microcytic anemia (Low MCV), normocytic anemia (Normal MCV) and macrocytic anemia (High MCV)
In terms of Route of Administration, the industry is divided into oral route and injectable route
In terms of distribution channel, the industry is segregated into hospital pharmacies, retail pharmacies and online pharmacies
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa (MEA) have been covered in the report.
The global anemia treatment industry is projected to witness CAGR of 5.9% between 2025 and 2035.
The global anemia treatment industry stood at USD 11,366.3 million in 2024.
The global anemia treatment industry is anticipated to reach USD 22.08 billion by 2035 end.
Japan is expected to show a CAGR of 5.4% in the assessment period.
The key players operating in the global anemia treatment industry include Amgen Inc., Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, AMAG Pharmaceuticals, Rockwell Medical, Akebia Therapeutics, Vifor Pharma Management Ltd.
Explore Therapy Area Insights
Anemia Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
